| Nov 7 |
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
|
| Nov 7 |
Moderna Slashes Hefty Premarket Gain With A Beat That's 'Not A Beat'
|
| Nov 6 |
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
|
| Nov 6 |
We Think You Can Look Beyond GSK's (LON:GSK) Lackluster Earnings
|
| Nov 2 |
M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
|
| Nov 2 |
GSK Third Quarter 2024 Earnings: EPS Misses Expectations
|
| Nov 1 |
Friday's FTSE 100 risers and fallers: Tesco, Frasers and EasyJet
|
| Oct 31 |
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses
|
| Oct 31 |
GSK downgraded at Guggenheim after Q3 sales drop
|
| Oct 31 |
GSK PLC (GSK) Q3 2024 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...
|
